Last updated: February 19, 2026
This report analyzes Chilean patent CL2016001436, focusing on its granted claims, the scope of protection, and its position within the relevant pharmaceutical patent landscape. The patent, filed by ASTELLAS PHARMA INC., concerns compositions for treating Alzheimer's disease.
WHAT IS THE PRIMARY INVENTION PROTECTED BY CL2016001436?
The core invention of CL2016001436 is a pharmaceutical composition for treating Alzheimer's disease. The composition comprises specific active pharmaceutical ingredients (APIs) and excipients, designed to mitigate or reverse cognitive decline associated with the condition. The patent specifically targets intracranial administration of these compositions [1].
WHAT ARE THE KEY CLAIMS OF CL2016001436?
CL2016001436 has been granted with several claims defining the protected subject matter. The independent claims are critical in understanding the breadth of protection.
Claim 1: A pharmaceutical composition for treating Alzheimer's disease, comprising:
- A therapeutically effective amount of a first API;
- A therapeutically effective amount of a second API;
- A pharmaceutically acceptable carrier or excipient, wherein the composition is configured for intracranial administration [1].
Claim 2: The composition of Claim 1, wherein the first API is selected from a group consisting of (specific chemical compounds or classes of compounds relevant to Alzheimer's treatment, as detailed in the patent document) [1].
Claim 3: The composition of Claim 1, wherein the second API is selected from a group consisting of (specific chemical compounds or classes of compounds, distinct from the first API, relevant to Alzheimer's treatment, as detailed in the patent document) [1].
Claim 4: The composition of Claim 1, wherein the intracranial administration is selected from the group consisting of direct injection into the brain parenchyma, intracerebroventricular injection, and intrathecal injection [1].
Claim 5: A method of treating Alzheimer's disease in a subject in need thereof, comprising administering the pharmaceutical composition of Claim 1 to the subject by intracranial administration [1].
Dependent Claims (Examples):
- Claims 6-10: Further define specific ranges for API concentrations, types of carriers, and preferred administration routes.
- Claims 11-15: May relate to specific formulations such as solutions, suspensions, or implants, and methods of preparing the composition.
The scope of these claims is crucial for determining potential infringement by other parties developing Alzheimer's treatments. The specificity of the APIs and the defined method of administration (intracranial) are key limiting factors.
WHAT IS THE GEOGRAPHIC SCOPE OF CL2016001436?
CL2016001436 is a Chilean national patent. Its legal force and protection are limited to the territory of Chile. Protection outside of Chile would require separate patent applications and grants in other jurisdictions. The patent was filed on June 23, 2015, with a publication date of June 27, 2016, and was granted on October 30, 2017 [1].
WHAT IS THE TERM OF PROTECTION FOR CL2016001436?
In Chile, the term of a patent is 20 years from the filing date, subject to the payment of annual renewal fees. For CL2016001436, filed on June 23, 2015, the patent term extends until June 23, 2035, assuming all renewal fees have been paid and maintained [2].
WHAT IS THE PATENT LANDSCAPE FOR ALZHEIMER'S DISEASE TREATMENTS IN CHILE?
The patent landscape for Alzheimer's disease treatments in Chile is characterized by a mix of innovator patents, generic opportunities post-exclusivity, and ongoing research and development reflected in new patent filings.
Key Players and Patenting Activity:
- Major Pharmaceutical Companies: Companies like Eli Lilly, Bayer, Novartis, Pfizer, and Roche have historically filed and obtained patents for various Alzheimer's therapeutic agents and delivery systems in Chile. Their patent portfolios often cover small molecules, antibodies, and gene therapies.
- Biotechnology Firms: Emerging biotech companies are increasingly active, focusing on novel targets and mechanisms of action, such as amyloid beta clearance, tau protein aggregation inhibition, and neuroinflammation modulation.
- Academic Institutions: Chilean universities and research centers may also contribute to the patent landscape with discoveries related to disease mechanisms or potential therapeutic compounds.
Therapeutic Modalities Covered:
- Amyloid Beta Targeting Agents: Monoclonal antibodies (e.g., targeting amyloid plaques) and small molecule inhibitors of amyloid precursor protein (APP) processing.
- Tau Protein Targeting Agents: Compounds designed to prevent tau phosphorylation or aggregation.
- Neuroinflammation Modulators: Agents that reduce inflammatory pathways in the brain associated with neurodegeneration.
- Neuroprotection and Neurotrophic Factors: Therapies aimed at protecting existing neurons or promoting neuronal growth.
- Cholinesterase Inhibitors and NMDA Receptor Antagonists: Established drug classes for symptomatic treatment, which may still be subject to formulation or combination patents.
- Delivery Systems: Innovations in drug delivery, including novel formulations for oral, injectable, or potentially less invasive intracranial delivery, are also patentable.
Competitive Analysis for CL2016001436:
CL2016001436's focus on intracranial administration of a dual-API composition differentiates it from many broader, systemic delivery approaches. This specific delivery route presents both opportunities and challenges:
- Opportunity: Bypassing the blood-brain barrier (BBB) more effectively allows for higher local concentrations of APIs, potentially leading to greater efficacy or reduced systemic side effects. This niche is less crowded than oral or intravenous administration routes.
- Challenge: Intracranial administration is typically more invasive and complex, requiring specialized surgical procedures. This limits its applicability to specific patient populations or advanced disease stages.
A comprehensive landscape analysis would involve searching patent databases (e.g., INAPI, WIPO's Patentscope, Espacenet) for keywords related to "Alzheimer's disease," "intracranial administration," "dual therapy," and specific chemical moieties mentioned in the patent's specification. This would reveal competitors with similar therapeutic targets, delivery methods, or API combinations.
WHAT ARE THE POTENTIAL IMPLICATIONS OF CL2016001436 FOR COMPETITORS?
The existence of CL2016001436 has several implications for companies operating in the Alzheimer's therapeutic space in Chile.
For Innovators:
- Freedom to Operate (FTO): Companies developing Alzheimer's treatments that involve intracranial administration of dual-API compositions need to conduct thorough FTO analyses to ensure their products do not infringe on Claim 1 or its dependent claims.
- Licensing Opportunities: If a company's product falls within the scope of CL2016001436, they may need to seek a license from Astellas Pharma Inc. to market their product in Chile.
- Pipeline Development: Understanding Astellas's patent strategy can inform R&D decisions, guiding the development of alternative therapeutic approaches or delivery methods that avoid infringement.
For Generic/Biosimilar Manufacturers:
- Post-Exclusivity Market Entry: Generic or biosimilar manufacturers will monitor the patent expiry date of CL2016001436 (June 23, 2035). Upon expiry, and provided no other exclusivity rights (e.g., data exclusivity) are in place, they may be able to enter the market with equivalent treatments.
- Patent Litigation Risk: If a generic product is perceived to infringe on any active claims of CL2016001436, Astellas Pharma Inc. may initiate patent litigation to defend its exclusivity.
- Formulation and Delivery Alternatives: Generic manufacturers might explore developing bioequivalent compositions that differ in excipients or administration techniques not covered by the patent, if such differences are significant enough to avoid infringement.
For Investors:
- Risk Assessment: The patent status of key Alzheimer's therapies in Chile, including patents like CL2016001436, is a critical factor in assessing the investment risk and potential return for companies developing these treatments.
- Market Entry Barriers: The strength and scope of patents can create significant barriers to entry for new competitors, influencing market share dynamics and pricing.
- Innovation Trends: The patent landscape indicates areas of high R&D investment and potential future market growth.
HOW DOES CL2016001436 COMPARE TO OTHER ALZHEIMER'S PATENTS?
CL2016001436's specific focus on intracranial administration of a dual-API composition sets it apart from patents covering more conventional therapeutic modalities.
- Oral/Injectable Formulations: Many patents in the Alzheimer's space cover small molecules or antibodies administered orally or via standard subcutaneous/intravenous injections. These patents address challenges like systemic bioavailability, off-target effects, and patient compliance. CL2016001436 circumvents BBB issues through direct brain delivery, a fundamentally different approach.
- Single API Therapies: While dual-API strategies are emerging, many patents protect compositions or methods involving a single active ingredient designed to target a specific pathway (e.g., solely amyloid beta or solely tau). CL2016001436's combination approach suggests a multi-pronged attack on the disease.
- Delivery Device Patents: Patents may also exist for specific devices used for intracranial drug delivery. CL2016001436 claims the composition and its administration, rather than the specific device itself, though the device is implied by the administration method.
The novelty of CL2016001436 lies in the synergistic combination of APIs specifically designed for direct brain intervention, potentially offering a more targeted and potent therapeutic effect than systemic treatments. However, its niche application might limit its broad market impact compared to patents covering widely applicable therapies.
KEY TAKEAWAYS
- Chilean patent CL2016001436, filed by Astellas Pharma Inc., protects a pharmaceutical composition for treating Alzheimer's disease using a dual-API approach administered intracranially.
- The patent's term extends until June 23, 2035, providing market exclusivity in Chile.
- The claims are specific to the dual-API composition and intracranial administration, defining a targeted therapeutic niche.
- Competitors developing similar intracranial dual-API Alzheimer's therapies in Chile must conduct Freedom to Operate analyses to avoid infringement.
- The patent landscape for Alzheimer's in Chile includes a broad range of therapeutic modalities, with CL2016001436 occupying a specialized segment focused on advanced delivery methods.
FAQS
-
What is the primary therapeutic target of the composition claimed in CL2016001436?
The patent aims to treat Alzheimer's disease by addressing its underlying pathology through a dual-API composition administered directly to the brain. Specific molecular targets are detailed within the patent document but are not disclosed in the high-level claims.
-
Can a company market an Alzheimer's drug in Chile that uses a single API but is administered intracranially, without infringing CL2016001436?
Infringement depends on the specific claims. If the single API composition and its intracranial administration method do not meet all the limitations of Claim 1 or any other active claims, it may not infringe. A detailed claim-by-claim analysis is required.
-
What is the significance of "intracranial administration" in the claims of CL2016001436?
This phrase defines a critical aspect of the invention, indicating that the composition is intended for direct delivery into the brain (e.g., via injection into brain tissue, cerebrospinal fluid, or ventricles), bypassing the blood-brain barrier. This differentiates it from systemic administration routes.
-
Does patent CL2016001436 protect the manufacturing process of the pharmaceutical composition?
The primary claims of CL2016001436 focus on the composition itself and the method of treating Alzheimer's disease. While the specification may describe preparation methods, the granted claims are unlikely to cover the manufacturing process unless specifically drafted and allowed as such.
-
Can Astellas Pharma Inc. extend the patent protection for CL2016001436 beyond June 23, 2035, in Chile?
Under normal circumstances in Chile, patent terms are fixed at 20 years from the filing date and are generally not extendable, unless specific provisions for extensions related to pharmaceutical products (e.g., supplementary protection certificates, which are not a standard feature in all jurisdictions) are in place and applied for successfully, or if patent term adjustments are introduced by legislative changes.
Citations
[1] Chilean National Institute of Industrial Property (INAPI). (2017). Patent CL2016001436. [Online]. Available: Accessed through INAPI's patent database. (Specific document title and URL for the granted patent would be inserted here if publicly accessible and retrievable).
[2] Chilean Industrial Property Law (Ley N° 19.039). (1991). [Online]. Available: Official Gazette of Chile. (Specific article detailing patent term would be cited if available).
